FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018012924> ?p ?o ?g. }

• W2018012924 endingPage "2097" @default.
• W2018012924 startingPage "2086" @default.
• W2018012924 abstract "Objective: The primary study objective was to determine whether insulin detemir (detemir) was noninferior to insulin glargine (glargine) as the basal insulin in a basal—bolus regimen, with insulin aspart as the mealtime insulin, in terms of glycemic control at the end of 52 weeks in patients with type 1 diabetes mellitus (T1DM). Methods: This multinational, open-label, parallel-group, treat-to-target, noninferiority trial enrolled patients aged ≥18 years who had had T1DM for at least 12 months, had been taking a basal—bolus insulin regimen for at least 3 months, and had a glycosylated hemoglobin (HbA1c) value ≤11.0% at screening. Patients were randomized in a 2:1 ratio to receive either detemir or glargine for 52 weeks. The basal insulin was initially administered once daily (in the evening) in both groups; if patients in the detemir group were achieving the plasma glucose (PG) target before breakfast but not before dinner, they were switched to twice-daily administration. Glargine was administered once daily throughout the trial, according to its approved labeling. Each patient attended 13 study visits and received 16 scheduled telephone calls from the trial site. The primary efficacy end point was glycemic control (HbA1c) after 52 weeks of treatment. Secondary end points included the number of patients achieving an HbA1c value ≤7.0%, with or without a major hypoglycemic episode in the last month of treatment; fasting PG (FPG); within-patient variation in self-monitored plasma glucose (SMPG) before breakfast and dinner; and 10-point SMPG profiles. The noninferiority margin was 0.4%, consistent with US Food and Drug Administration guidelines. Results: Four hundred forty-three patients (mean [SD] age, 42 [12] years; body mass index, 26.5 [4.0] kg/m2; duration of diabetes, 17.2 [11.4] years; HbA1c, 8.1% [1.1%]) received study treatment. After 52 weeks, the estimated mean HbA1c did not differ significantly between the detemir and glargine groups (7.57% and 7.56%, respectively; mean difference, 0.01%; 95% CI, −0.13 to 0.16), consistent with the noninferiority of detemir to glargine. The corresponding estimated changes in HbA1c were −0.53% and −0.54%. In the 90 patients who completed the trial on once-daily detemir and the 173 patients who completed the trial on twice-daily detemir, the estimated changes in HbA1c were −0.49% and −0.58%, respectively. After 52 weeks, there were no significant differences in the proportions of those receiving detemir and glargine who achieved an HbA1c value ≤7.0% without major hypoglycemia (31.9% and 28.9%, respectively). In addition, there were no significant differences in estimated mean FPG (8.58 and 8.81 mmol/L; mean difference, −0.23 mmol/L; 95% CI, −1.04 to 0.58) or in basal insulin doses. The basal insulin dose was numerically higher in patients receiving detemir twice rather than once daily (0.47 vs 0.33 U/kg, respectively). The relative risks for total and nocturnal hypoglycemia with detemir versus glargine were 0.94 and 1.12, respectively (both, P = NS). Six patients (2.0%) randomized to the detemir group and 4 (2.7%) randomized to the glargine group withdrew due to adverse events. Conclusions: During 52 weeks of basal—bolus therapy in patients with T1DM, detemir was noninferior to glargine in terms of overall glycemic control (HbA1c). When used according to the approved labeling, detemir and glargine did not differ in tolerability or in terms of the occurrence of hypoglycemia." @default.
• W2018012924 created "2016-06-24" @default.
• W2018012924 creator A5005036709 @default.
• W2018012924 creator A5052889466 @default.
• W2018012924 creator A5065414735 @default.
• W2018012924 date "2009-10-01" @default.
• W2018012924 modified "2023-09-30" @default.
• W2018012924 title "Comparison of insulin detemir and insulin glargine in a basal—bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority trial" @default.
• W2018012924 cites W1971264172 @default.
• W2018012924 cites W1971493468 @default.
• W2018012924 cites W1983639156 @default.
• W2018012924 cites W2008449957 @default.
• W2018012924 cites W2011931322 @default.
• W2018012924 cites W2032666450 @default.
• W2018012924 cites W2043324706 @default.
• W2018012924 cites W2058777107 @default.
• W2018012924 cites W2065518778 @default.
• W2018012924 cites W2071173797 @default.
• W2018012924 cites W2084807176 @default.
• W2018012924 cites W2086666326 @default.
• W2018012924 cites W2125788080 @default.
• W2018012924 cites W2129121181 @default.
• W2018012924 cites W2136164787 @default.
• W2018012924 cites W2138112294 @default.
• W2018012924 cites W2154661744 @default.
• W2018012924 cites W3216474499 @default.
• W2018012924 cites W4243765000 @default.
• W2018012924 doi "https://doi.org/10.1016/j.clinthera.2009.10.006" @default.
• W2018012924 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19922879" @default.
• W2018012924 hasPublicationYear "2009" @default.
• W2018012924 type Work @default.
• W2018012924 sameAs 2018012924 @default.
• W2018012924 citedByCount "85" @default.
• W2018012924 countsByYear W20180129242012 @default.
• W2018012924 countsByYear W20180129242013 @default.
• W2018012924 countsByYear W20180129242014 @default.
• W2018012924 countsByYear W20180129242015 @default.
• W2018012924 countsByYear W20180129242016 @default.
• W2018012924 countsByYear W20180129242017 @default.
• W2018012924 countsByYear W20180129242018 @default.
• W2018012924 countsByYear W20180129242019 @default.
• W2018012924 countsByYear W20180129242020 @default.
• W2018012924 countsByYear W20180129242021 @default.
• W2018012924 countsByYear W20180129242022 @default.
• W2018012924 crossrefType "journal-article" @default.
• W2018012924 hasAuthorship W2018012924A5005036709 @default.
• W2018012924 hasAuthorship W2018012924A5052889466 @default.
• W2018012924 hasAuthorship W2018012924A5065414735 @default.
• W2018012924 hasBestOaLocation W20180129242 @default.
• W2018012924 hasConcept C126322002 @default.
• W2018012924 hasConcept C134018914 @default.
• W2018012924 hasConcept C168563851 @default.
• W2018012924 hasConcept C203092338 @default.
• W2018012924 hasConcept C2777180221 @default.
• W2018012924 hasConcept C2779306644 @default.
• W2018012924 hasConcept C2779908123 @default.
• W2018012924 hasConcept C2779920387 @default.
• W2018012924 hasConcept C2780473172 @default.
• W2018012924 hasConcept C2780668416 @default.
• W2018012924 hasConcept C2780677441 @default.
• W2018012924 hasConcept C2781232474 @default.
• W2018012924 hasConcept C2781413609 @default.
• W2018012924 hasConcept C555293320 @default.
• W2018012924 hasConcept C71924100 @default.
• W2018012924 hasConceptScore W2018012924C126322002 @default.
• W2018012924 hasConceptScore W2018012924C134018914 @default.
• W2018012924 hasConceptScore W2018012924C168563851 @default.
• W2018012924 hasConceptScore W2018012924C203092338 @default.
• W2018012924 hasConceptScore W2018012924C2777180221 @default.
• W2018012924 hasConceptScore W2018012924C2779306644 @default.
• W2018012924 hasConceptScore W2018012924C2779908123 @default.
• W2018012924 hasConceptScore W2018012924C2779920387 @default.
• W2018012924 hasConceptScore W2018012924C2780473172 @default.
• W2018012924 hasConceptScore W2018012924C2780668416 @default.
• W2018012924 hasConceptScore W2018012924C2780677441 @default.
• W2018012924 hasConceptScore W2018012924C2781232474 @default.
• W2018012924 hasConceptScore W2018012924C2781413609 @default.
• W2018012924 hasConceptScore W2018012924C555293320 @default.
• W2018012924 hasConceptScore W2018012924C71924100 @default.
• W2018012924 hasFunder F4320322436 @default.
• W2018012924 hasIssue "10" @default.
• W2018012924 hasLocation W20180129241 @default.
• W2018012924 hasLocation W20180129242 @default.
• W2018012924 hasLocation W20180129243 @default.
• W2018012924 hasOpenAccess W2018012924 @default.
• W2018012924 hasPrimaryLocation W20180129241 @default.
• W2018012924 hasRelatedWork W2004643446 @default.
• W2018012924 hasRelatedWork W2068789151 @default.
• W2018012924 hasRelatedWork W2077148563 @default.
• W2018012924 hasRelatedWork W2097704951 @default.
• W2018012924 hasRelatedWork W2149194615 @default.
• W2018012924 hasRelatedWork W2197938513 @default.
• W2018012924 hasRelatedWork W2315328579 @default.
• W2018012924 hasRelatedWork W2371880537 @default.
• W2018012924 hasRelatedWork W2416228359 @default.
• W2018012924 hasRelatedWork W2577825165 @default.
• W2018012924 hasVolume "31" @default.
• W2018012924 isParatext "false" @default.

• next